By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Infinity Pharmaceuticals Inc. 

780 Memorial Drive

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-453-1000 Fax: 617-453-1001


SEARCH JOBS
The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.

Small molecule discovery and development capabilities
Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.

Strategic alliances
Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.

Business and scientific expertise
The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.

Culture of Citizen-Ownership
Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.


Key Statistics


Email: info@infi.com
Ownership: Public

Web Site: Infinity Pharma
Employees: 180
Symbol: INFI
 



Industry
Biotechnology

Segment
Oncology





Company News
Infinity Pharma (INFI) Provides Company Update And Reports Third Quarter 2016 Financial Results 11/10/2016 4:54:11 PM
Infinity Pharma (INFI) Announces Second Publication On PI3K-Gamma In Nature 11/10/2016 3:16:31 PM
Bristol-Myers Squibb (BMY) And Infinity Pharma (INFI) Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors 11/9/2016 9:45:11 AM
Infinity Pharma (INFI) Moves The Date Of Its Third Quarter 2016 Financial Results Conference Call And Webcast 11/4/2016 9:10:52 AM
Verastem (VSTM) Licenses Duvelisib From Infinity Pharma (INFI) 11/2/2016 10:48:58 AM
Verastem (VSTM) Licenses Duvelisib From Infinity Pharma (INFI) 11/2/2016 7:17:16 AM
Infinity Pharma (INFI) Announces The Date Of Its Third Quarter 2016 Financial Results Conference Call And Webcast 10/31/2016 8:50:44 AM
Infinity Pharma (INFI) Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/27/2016 7:40:59 AM
Infinity Pharma (INFI) Announces Publication On PI3K-Gamma In Nature 9/19/2016 11:18:43 AM
Infinity Pharma (INFI) Announces Presentations On IPI-549 At Upcoming Immuno-Oncology Meeting 9/6/2016 1:36:07 PM
12345678910...
//-->